Incidence and risk factors for recurrent focal segmental glomerulosclerosis after kidney transplantation: a meta-analysis

References

• Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12(3):1–12.
   PubMed Web of Science ®Google Scholar
• Savin VJ, Sharma M, Zhou J, et al. Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family. J Immunol Res. 2015;2015:714964.
   PubMed Web of Science ®Google Scholar
• Lopez-Hellin J, Cantarell C, Jimeno L, et al. A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation. Am J Transplant. 2013;13(2):493–500.
   PubMed Web of Science ®Google Scholar
• Delville M, Sigdel TK, Wei C, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014;6(256):136r–256r.
   Web of Science ®Google Scholar
• Wei C, El HS, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952–960.
   PubMed Web of Science ®Google Scholar
• Harris JJ, McCarthy HJ, Ni L, et al. Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1. J Pathol. 2013;229(5):660–671.
   PubMed Web of Science ®Google Scholar
• Kachurina N, Chung CF, Benderoff E, et al. Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis. Am J Physiol Renal Physiol. 2016;310(10):F1148–F1156.
   PubMed Web of Science ®Google Scholar
• Troost JP, Trachtman H, Spino C, et al. Proteinuria reduction and kidney survival in focal segmental glomerulosclerosis. Am J Kidney Dis. 2021;77(2):216–225.
   PubMed Web of Science ®Google Scholar
• Rudnicki M. FSGS recurrence in adults after renal transplantation. Biomed Res Int. 2016;2016:3295618.
   PubMed Web of Science ®Google Scholar
• Kienzl-Wagner K, Waldegger S, Schneeberger S. disease recurrence-the sword of damocles in kidney transplantation for primary focal segmental glomerulosclerosis. Front Immunol. 2019;10:1669.
   PubMed Web of Science ®Google Scholar
• Yamamoto I, Yamakawa T, Katsuma A, et al. Recurrence of native kidney disease after kidney transplantation. Nephrology. 2018;23(Suppl 2):27–30.
   PubMedGoogle Scholar
• Harel E, Shoji J, Abraham V, et al. Further evidence that the soluble urokinase plasminogen activator receptor does not directly injure mice or human podocytes. Transplantation. 2020;104(1):54–60.
   PubMed Web of Science ®Google Scholar
• Miao J, Krisanapan P, Tangpanithandee S, et al. Efficacy of extracorporeal plasma therapy for adult native kidney patients with primary FSGS: a systematic review. Ren Fail. 2023;45(1):2176694.
   PubMed Web of Science ®Google Scholar
• Chen YY, Sun X, Huang W, et al. Therapeutic apheresis in kidney diseases: an updated review. Ren Fail. 2022;44(1):842–857.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• Murad MH, Wang Z, Chu H, et al. When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation. BMJ. 2019;364:k4817.
   PubMedGoogle Scholar
• Puig-Gay N, Jacobs-Cacha C, Sellares J, et al. Apolipoprotein A-Ib as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value – a multi-centre cohort study. Transpl Int. 2019;32(3):313–322.
   PubMed Web of Science ®Google Scholar
• Harel E, Shoji J, Abraham V, et al. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation. Clin Transplant. 2019;33(3):e13487.
   PubMed Web of Science ®Google Scholar
• Alasfar S, Matar D, Montgomery RA, et al. Rituximab and therapeutic plasma exchange in recurrent focal segmental glomerulosclerosis postkidney transplantation. Transplantation. 2018;102(3):e115–e120.
   PubMed Web of Science ®Google Scholar
• Cormican S, Kennedy C, O’Kelly P, et al. Renal transplant outcomes in primary FSGS compared with other recipients and risk factors for recurrence: a national review of the Irish transplant registry. Clin Transplant. 2018;32(1):e13152.
   Web of Science ®Google Scholar
• Mujtaba MA, Sharfuddin AA, Book BL, et al. Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence. Clin Transplant. 2015;29(7):606–611.
   PubMed Web of Science ®Google Scholar
• Park HS, Hong Y, Sun IO, et al. Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients. Korean J Intern Med. 2014;29(4):482–488.
   PubMed Web of Science ®Google Scholar
• Straatmann C, Kallash M, Killackey M, et al. Success with plasmapheresis treatment for recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients. Pediatr Transplant. 2014;18(1):29–34.
   PubMed Web of Science ®Google Scholar
• Franco PC, Lieske JC, Wadei HM, et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation. 2013;96(4):394–399.
   PubMed Web of Science ®Google Scholar
• Shishido S, Satou H, Muramatsu M, et al. Combination of pulse methylprednisolone infusions with cyclosporine-based immunosuppression is safe and effective to treat recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation. Clin Transplant. 2013;27(2):E143–50.
   PubMed Web of Science ®Google Scholar
• Maas RJ, Deegens JK, van den Brand JA, et al. A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation. BMC Nephrol. 2013;14:47.
   PubMed Web of Science ®Google Scholar
• Ingulli E, Tejani A. Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children–a single-center experience. Transplantation. 1991;51(2):401–405.
   PubMed Web of Science ®Google Scholar
• Pinto J, Lacerda G, Cameron JS, et al. Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation. 1981;32(2):83–89.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Ha J, Jung IM, et al. Recurrent focal segmental glomerulosclerosis following renal transplantation in Korean pediatric patients. Pediatr Transplant. 2001;5(2):105–111.
   PubMed Web of Science ®Google Scholar
• Fujisawa M, Iijima K, Ishimura T, et al. Long-term outcome of focal segmental glomerulosclerosis after Japanese pediatric renal transplantation. Pediatr Nephrol. 2002;17(3):165–168.
   PubMed Web of Science ®Google Scholar
• Sener A, Bella AJ, Nguan C, et al. Focal segmental glomerular sclerosis in renal transplant recipients: predicting early disease recurrence may prolong allograft function. Clin Transplant. 2009;23(1):96–100.
   PubMed Web of Science ®Google Scholar
• Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation. 2009;87(8):1232–1239.
   PubMed Web of Science ®Google Scholar
• Vallianou K, Marinaki S, Skalioti C, et al. Therapeutic options for recurrence of primary focal segmental glomerulonephritis (FSGS) in the renal allograft: single-Center experience. J Clin Med. 2021;10(3):373.
   PubMed Web of Science ®Google Scholar
• Pardon A, Audard V, Caillard S, et al. Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol Dial Transplant. 2006;21(4):1053–1059.
   PubMed Web of Science ®Google Scholar
• Uffing A, Perez-Saez MJ, Mazzali M, et al. Recurrence of FSGS after kidney transplantation in adults. Clin J Am Soc Nephrol. 2020;15(2):247–256.
   PubMed Web of Science ®Google Scholar
• Baskın E, Avcı B, Gülleroğlu K, et al. Primary focal segmental glomerulosclerosis recurrence after pediatric renal transplantation. Exp Clin Transplant. 2022;20(Suppl 1):55–60.
   PubMedGoogle Scholar
• Huang K, Ferris ME, Andreoni KA, et al. The differential effect of race among pediatric kidney transplant recipients with focal segmental glomerulosclerosis. Am J Kidney Dis. 2004;43(6):1082–1090.
   PubMed Web of Science ®Google Scholar
• Mahesh S, Del RM, Feuerstein D, et al. Demographics and response to therapeutic plasma exchange in pediatric renal transplantation for focal glomerulosclerosis: a single center experience. Pediatr Transplant. 2008;12(6):682–688.
   PubMed Web of Science ®Google Scholar
• Schachter ME, Monahan M, Radhakrishnan J, et al. Recurrent focal segmental glomerulosclerosis in the renal allograft: single center experience in the era of modern immunosuppression. Clin Nephrol. 2010;74(3):173–181.
   PubMed Web of Science ®Google Scholar
• Bai J, Yang JY, Di JK, et al. Gender and socioeconomic disparities in global burden of chronic kidney disease due to glomerulonephritis: a global analysis. Nephrology. 2023;28(3):159–167.
   PubMed Web of Science ®Google Scholar
• Cameron JS. Recurrent primary disease and de novo nephritis following renal transplantation. Pediatr Nephrol. 1991;5(4):412–421.
   PubMed Web of Science ®Google Scholar
• Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. Pediatr Nephrol. 2007;22(12):1999–2009.
   PubMed Web of Science ®Google Scholar
• Ruospo M, Palmer SC, Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018;8(8):D6023.
   Google Scholar
• Ruospo M, Saglimbene VM, Palmer SC, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev. 2017;6(6):D10137.
   Google Scholar
• Kashgary A, Sontrop JM, Li L, et al. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrol. 2016;17(1):104.
   PubMedGoogle Scholar
• Hansrivijit P, Ghahramani N. Combined rituximab and plasmapheresis or plasma exchange for focal segmental glomerulosclerosis in adult kidney transplant recipients: a meta-analysis. Int Urol Nephrol. 2020;52(7):1377–1387.
   PubMed Web of Science ®Google Scholar
• Baum MA, Stablein DM, Panzarino VM, et al. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int. 2001;59(1):328–333.
   PubMed Web of Science ®Google Scholar
• Shoji J, Mii A, Terasaki M, et al. Update on recurrent focal segmental glomerulosclerosis in kidney transplantation. Nephron. 2020;144(Suppl 1):65–70.
   PubMed Web of Science ®Google Scholar
• Bai J, Wu Q, Chen J, et al. Risk factors for recurrent IgA nephropathy after renal transplantation: a meta-analysis. Bosn J Basic Med Sci. 2022. Online ahead of print.
   PubMedGoogle Scholar
• Morin G, Legendre C, Canaud G. Management of post-transplant recurrent focal and segmental glomerulosclerosis. Nephrol Dial Transplant. 2021;36(11):1994–1996.
   PubMed Web of Science ®Google Scholar
• Trachtman R, Sran SS, Trachtman H. Recurrent focal segmental glomerulosclerosis after kidney transplantation. Pediatr Nephrol. 2015;30(10):1793–1802.
   PubMed Web of Science ®Google Scholar
• Korbet SM. The treatment of primary focal segmental glomerulosclerosis. Ren Fail. 2000;22(6):685–696.
   PubMed Web of Science ®Google Scholar